Tune Therapeutics
Andrew Spreckman is a skilled Process Engineer and Scientist currently working at Tune Therapeutics since September 2023. Prior experience includes a role as Senior Engineer in MS&T at Moderna from September 2021 to April 2023, and a significant tenure at Pfizer from November 2015 to September 2021, where responsibilities included serving as Technical Project Lead, Tech Transfer Coordinator, Engineer II, and Engineer I. In early 2015, Andrew completed an internship at Rain CII Carbon LLC. Andrew holds dual degrees in Chemical Engineering, a Bachelor of Engineering (B.E.) and a Bachelor of Science, both earned from Tulane University between 2011 and 2015.
Tune Therapeutics
1 followers
With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.